The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under
development for the treatment of type 2 diabetes (T2D) and obesity. Its association with …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Background We aimed to assess efficacy and safety, with a special focus on cardiovascular
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …

Background Data are lacking on the comparative effectiveness of commonly used glucose-
lowering medications, when added to metformin, with respect to microvascular and …

Dawn O. Kleindorfer, MD, FAHA, Chair; Amytis Towfighi, MD, FAHA, Vice Chair; Seemant
Chaturvedi, MD, FAHA; Kevin M. Cockroft, MD, MSc, FAHA; Jose Gutierrez, MD, MPH; …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

The endothelium, a cellular monolayer lining the blood vessel wall, plays a critical role in
maintaining multiorgan health and homeostasis. Endothelial functions in health include …